Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3:  Multivariable analysis for participants with previous cerebrovascular ischemic events^a
Multivariable
OR 95% CI P
Age (yr) 0.99 0.91–1.08 .88
Female 0.43 0.07–2.72 .37
Active smoker 7.50 1.10–51.47 .04
Diabetes mellitus 10.25 0.91–115.92 .06
Hypertension 0.58 0.10–3.34 .54
Hyperlipidemia 0.51 0.08–3.14 .47
Statin use 0.81 0.06–9.84 .87
Aspirin use 0.99 0.10–9.70 .99
Stenosis (%) 0.05 0.02–1.50 .09
Maximum wall thickness (mm) 0.77 0.40–1.45 .42
Adventitial enhancement (category 1 vs category 0) 14.90 0.98–225.93 .05
Adventitial enhancement (category 2 vs category 0) 51.17 3.40–469.80 .004
IPH presence 10.18 1.42–72.21 .02


↵a Adjusting for coils and gadolinium dose.

	Multivariable
	OR	95% CI	P
Age (yr)	0.99	0.91–1.08	.88
Female	0.43	0.07–2.72	.37
Active smoker	7.50	1.10–51.47	.04
Diabetes mellitus	10.25	0.91–115.92	.06
Hypertension	0.58	0.10–3.34	.54
Hyperlipidemia	0.51	0.08–3.14	.47
Statin use	0.81	0.06–9.84	.87
Aspirin use	0.99	0.10–9.70	.99
Stenosis (%)	0.05	0.02–1.50	.09
Maximum wall thickness (mm)	0.77	0.40–1.45	.42
Adventitial enhancement (category 1 vs category 0)	14.90	0.98–225.93	.05
Adventitial enhancement (category 2 vs category 0)	51.17	3.40–469.80	.004
IPH presence	10.18	1.42–72.21	.02